Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific reports positive real-world data for Precision Spectra system

Boston Scientific reports positive real-world data for Precision Spectra system

11th December 2013

Boston Scientific has presented new data from a real-world study that underlines the benefits provided by its Precision Spectra spinal cord stimulator (SCS) system.

The retrospective study of up to 213 consecutive patients at 13 centres focused on patients with chronic pain who were treated with Precision Spectra. It was found that they experienced highly significant pain relief three months after implantation.

Results from the trial showed the device was associated with a 94 percent therapy success rate, with patients experiencing improvements in function, including walking and sleeping, in addition to reductions in opioid use and disability.

Precision Spectra is the first SCS system that uses the innovative and advanced Illumina 3D Software, a 3D anatomy-driven computer model.

Maulik Nanavaty, president of neuromodulation at Boston Scientific, said: "This data is very promising and we look forward to the results of our ongoing clinical programmes to demonstrate the long term benefits of the Precision Spectra SCS system."

This comes after the company received European CE Mark approval for its Vercise deep brain stimulation system last month.ADNFCR-8000103-ID-801671281-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.